Natixis Advisors’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$121M Buy
954,962
+3,055
+0.3% +$403K 0.14% 149
2026
Q1
$133M Buy
951,907
+175,668
+23% +$24.6M 0.18% 123
2025
Q4
$95.3M Buy
776,239
+129,843
+20% +$15.8M 0.14% 156
2025
Q3
$71.8M Buy
646,396
+17,725
+3% +$2.01M 0.1% 195
2025
Q2
$69.7M Buy
628,671
+128,488
+26% +$13.7M 0.11% 194
2025
Q1
$56M Buy
500,183
+165,446
+49% +$17.1M 0.1% 206
2024
Q4
$30.9M Buy
334,737
+165,374
+98% +$14.9M 0.06% 320
2024
Q3
$14.2M Buy
169,363
+25,912
+18% +$1.98M 0.03% 546
2024
Q2
$9.84M Sell
143,451
-35,988
-20% -$2.4M 0.02% 611
2024
Q1
$13.1M Sell
179,439
-100,181
-36% -$7.7M 0.03% 520
2023
Q4
$22.7M Buy
279,620
+36,711
+15% +$2.86M 0.06% 325
2023
Q3
$18.2M Sell
242,909
-2,082
-0.8% -$160K 0.06% 343
2023
Q2
$18.9M Sell
244,991
-9,610
-4% -$766K 0.06% 339
2023
Q1
$21.1M Buy
254,601
+59,489
+30% +$4.93M 0.07% 287
2022
Q4
$16.8M Buy
195,112
+35,725
+22% +$2.83M 0.06% 337
2022
Q3
$9.83M Buy
159,387
+22,941
+17% +$1.45M 0.04% 438
2022
Q2
$8.43M Buy
136,446
+68,104
+100% +$4.22M 0.04% 483
2022
Q1
$4.06M Sell
68,342
-97,689
-59% -$6.24M 0.02% 747
2021
Q4
$12.1M Buy
166,031
+24,324
+17% +$1.68M 0.05% 404
2021
Q3
$9.9M Buy
141,707
+3,640
+3% +$256K 0.04% 424
2021
Q2
$9.51M Buy
138,067
+27,658
+25% +$1.85M 0.04% 424
2021
Q1
$7.13M Buy
110,409
+24,550
+29% +$1.58M 0.04% 480
2020
Q4
$5M Sell
85,859
-15,941
-16% -$962K 0.03% 558
2020
Q3
$6.43M Sell
101,800
-66,944
-40% -$4.64M 0.04% 441
2020
Q2
$13M Sell
168,744
-18,688
-10% -$1.43M 0.09% 265
2020
Q1
$14M Buy
187,432
+97,251
+108% +$6.72M 0.11% 204
2019
Q4
$5.86M Sell
90,181
-7,193
-7% -$468K 0.04% 475
2019
Q3
$6.17M Sell
97,374
-686
-0.7% -$44.8K 0.05% 411
2019
Q2
$6.63M Buy
98,060
+13,175
+16% +$867K 0.05% 377
2019
Q1
$5.52M Sell
84,885
-14,355
-14% -$954K 0.05% 420
2018
Q4
$6.21M Sell
99,240
-1,296
-1% -$90.6K 0.06% 339
2018
Q3
$7.76M Sell
100,536
-41,137
-29% -$3.11M 0.07% 319
2018
Q2
$10M Sell
141,673
-12,811
-8% -$905K 0.1% 249
2018
Q1
$11.6M Buy
154,484
+23,256
+18% +$1.85M 0.12% 200
2017
Q4
$9.4M Sell
131,228
-15,288
-10% -$1.16M 0.1% 249
2017
Q3
$11.9M Buy
146,516
+39,009
+36% +$2.98M 0.13% 193
2017
Q2
$7.61M Sell
107,507
-1,061
-1% -$70.6K 0.08% 287
2017
Q1
$7.37M Buy
108,568
+3,272
+3% +$230K 0.08% 297
2016
Q4
$7.54M Sell
105,296
-17,662
-14% -$1.31M 0.09% 274
2016
Q3
$9.73M Sell
122,958
-46,470
-27% -$3.77M 0.13% 204
2016
Q2
$14.1M Buy
169,428
+14,813
+10% +$1.31M 0.2% 125
2016
Q1
$14.2M Buy
154,615
+25,817
+20% +$2.33M 0.21% 109
2015
Q4
$13M Sell
128,798
-15,360
-11% -$1.6M 0.21% 100
2015
Q3
$14.2M Sell
144,158
-12,717
-8% -$1.41M 0.25% 80
2015
Q2
$18.4M Buy
156,875
+9,445
+6% +$1.03M 0.31% 56
2015
Q1
$14.5M Buy
147,430
+14,029
+11% +$1.42M 0.25% 80
2014
Q4
$12.6M Buy
133,401
+14,610
+12% +$1.51M 0.24% 88
2014
Q3
$12.6M Buy
118,791
+7,441
+7% +$729K 0.25% 76
2014
Q2
$9.23M Buy
111,350
+9,801
+10% +$763K 0.13% 238
2014
Q1
$7.2M Sell
101,549
-6,389
-6% -$501K 0.11% 311
2013
Q4
$8.11M Buy
107,938
+9,828
+10% +$684K 0.13% 248
2013
Q3
$6.17M Buy
98,110
+9,652
+11% +$577K 0.11% 307
2013
Q2
$4.54M Buy
+88,458
New +$4.61M 0.09% 368

Other funds holding GILD

Natixis Advisors's GILD Position: Q2 2026 in Review

Natixis Advisors increased its Gilead Sciences (GILD) stake by 0.32% in Q2 2026, buying an estimated $403K and bringing the position to 954,962 shares worth $121M. The position accounts for 0.14% of the portfolio, ranked #149.

Natixis Advisors first reported a position in GILD in Q2 2013 and has held it in 53 quarters since. The position peaked at $133M in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Natixis Advisors held 954,962 shares of Gilead Sciences worth $121M as of Q2 2026.
  • Natixis Advisors bought 3,055 Gilead Sciences shares in Q2 2026, an estimated $403K.
  • Gilead Sciences made up 0.14% of Natixis Advisors's portfolio in Q2 2026, its #149 holding.
  • Natixis Advisors first reported a position in Gilead Sciences in Q2 2013 and has held it in 53 quarters since.
  • Natixis Advisors's Gilead Sciences position peaked at $133M in Q1 2026.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Natixis Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.